If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> EUROPEAN MEDICAL JOURNAL<br /> ISSN 2397-6764 Vol 1.4 • December 2016 • emjreviews.com<br /> CONTENTS<br /> EDITORIAL BOARD...................................................................................................................................... 4<br /> FEATURE<br /> • SEDENTARY BEHAVIOUR: A NEW TARGET IN THE PREVENTION AND MANAGEMENT<br /> OF DIABETES?......................................................................................................................................... 12<br /> Julianne D. van der Berg et al.<br /> SYMPOSIUM REVIEW<br /> • OPTIMISING RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR THERAPY IN<br /> HEART FAILURE AND RESISTANT HYPERTENSION: CHALLENGES AND SOLUTIONS........ 19<br /> ARTICLES<br /> • EDITOR’S PICK: OCULAR MANIFESTATIONS OF WHIPLASH INJURY....................................... 27<br /> Celeste Yong Pei L<a title="EMJ 1.4 2016 page 1" href="http://viewer.zmags.com/publication/8d83f42a?page=1"> EUROPEAN MEDICAL JOURNAL ISSN 2397-6764 </a> <a title="EMJ 1.4 2016 page 2" href="http://viewer.zmags.com/publication/8d83f42a?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ 1.4 2016 page 3" href="http://viewer.zmags.com/publication/8d83f42a?page=3"> EUROPEAN MEDICAL JOURNAL • CLINICAL MANAGEMENT </a> <a title="EMJ 1.4 2016 page 4" href="http://viewer.zmags.com/publication/8d83f42a?page=4"> Editorial Board Editor-in-Chief: Markus Peck-Ra</a> <a title="EMJ 1.4 2016 page 5" href="http://viewer.zmags.com/publication/8d83f42a?page=5"> European Medical Journal Ian Chikanza, Consul</a> <a title="EMJ 1.4 2016 page 6" href="http://viewer.zmags.com/publication/8d83f42a?page=6"> EUROPEAN MEDICAL JOURNAL 1.4 DECEMBER 2016 Direc</a> <a title="EMJ 1.4 2016 page 7" href="http://viewer.zmags.com/publication/8d83f42a?page=7"> Welcome Greetings and welcome to our fourth an</a> <a title="EMJ 1.4 2016 page 8" href="http://viewer.zmags.com/publication/8d83f42a?page=8"> I AM “ON” ! NEW AND REUSABLE The new reusab</a> <a title="EMJ 1.4 2016 page 9" href="http://viewer.zmags.com/publication/8d83f42a?page=9"> Foreword </a> <a title="EMJ 1.4 2016 page 10" href="http://viewer.zmags.com/publication/8d83f42a?page=10"> Giving you the ability to shape optimal outc </a> <a title="EMJ 1.4 2016 page 11" href="http://viewer.zmags.com/publication/8d83f42a?page=11"> omes is the recommended arting dose for patients</a> <a title="EMJ 1.4 2016 page 12" href="http://viewer.zmags.com/publication/8d83f42a?page=12"> SEDENTARY BEHAVIOUR: A NEW TARGET IN THE PREVENTI</a> <a title="EMJ 1.4 2016 page 13" href="http://viewer.zmags.com/publication/8d83f42a?page=13"> activity and sedentary behaviour. This provi</a> <a title="EMJ 1.4 2016 page 14" href="http://viewer.zmags.com/publication/8d83f42a?page=14"> 58% 60% Normal glucose metabolism </a> <a title="EMJ 1.4 2016 page 15" href="http://viewer.zmags.com/publication/8d83f42a?page=15"> activity (running). The effect of reducing sedent</a> <a title="EMJ 1.4 2016 page 16" href="http://viewer.zmags.com/publication/8d83f42a?page=16"> IMPLICATIONS FOR PUBLIC HEALTH AND CLINICAL PRACT</a> <a title="EMJ 1.4 2016 page 17" href="http://viewer.zmags.com/publication/8d83f42a?page=17"> 32. Falconer CL et al. The Potential Impact of Di</a> <a title="EMJ 1.4 2016 page 18" href="http://viewer.zmags.com/publication/8d83f42a?page=18"> In asthma and COPD </a> <a title="EMJ 1.4 2016 page 19" href="http://viewer.zmags.com/publication/8d83f42a?page=19"> OPTIMISING RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM </a> <a title="EMJ 1.4 2016 page 20" href="http://viewer.zmags.com/publication/8d83f42a?page=20"> only reducing serum potassium levels for a </a> <a title="EMJ 1.4 2016 page 21" href="http://viewer.zmags.com/publication/8d83f42a?page=21"> Decreased Decreased renal bloo</a> <a title="EMJ 1.4 2016 page 22" href="http://viewer.zmags.com/publication/8d83f42a?page=22"> RAAS inhibitors were also shown to reduce m</a> <a title="EMJ 1.4 2016 page 23" href="http://viewer.zmags.com/publication/8d83f42a?page=23"> A retrospective analysis of hypertensive patients</a> <a title="EMJ 1.4 2016 page 24" href="http://viewer.zmags.com/publication/8d83f42a?page=24"> and magnesium than for potassium.31 Therefor</a> <a title="EMJ 1.4 2016 page 25" href="http://viewer.zmags.com/publication/8d83f42a?page=25"> New Agents: Unanswered Questions and C</a> <a title="EMJ 1.4 2016 page 26" href="http://viewer.zmags.com/publication/8d83f42a?page=26"> of nationwide registry data. Eur Heart J. 2016. [</a> <a title="EMJ 1.4 2016 page 27" href="http://viewer.zmags.com/publication/8d83f42a?page=27"> EDITOR’S PICK A to</a> <a title="EMJ 1.4 2016 page 28" href="http://viewer.zmags.com/publication/8d83f42a?page=28"> INTRODUCTION Whiplash injuries are the most comm</a> <a title="EMJ 1.4 2016 page 29" href="http://viewer.zmags.com/publication/8d83f42a?page=29"> Table 2: Common ocular clinical symptoms and sign</a> <a title="EMJ 1.4 2016 page 30" href="http://viewer.zmags.com/publication/8d83f42a?page=30"> Delayed presentation of abducens nerve palsy</a> <a title="EMJ 1.4 2016 page 31" href="http://viewer.zmags.com/publication/8d83f42a?page=31"> Horner’s syndrome Horner’s syndrome was noted in </a> <a title="EMJ 1.4 2016 page 32" href="http://viewer.zmags.com/publication/8d83f42a?page=32"> and hydrostatic pressure in the intraoc</a> <a title="EMJ 1.4 2016 page 33" href="http://viewer.zmags.com/publication/8d83f42a?page=33"> comparative study. J Neurol Neurosurg Psychiatry.</a> <a title="EMJ 1.4 2016 page 34" href="http://viewer.zmags.com/publication/8d83f42a?page=34"> RECENT DEVELOPMENTS IN REGORAFENIB TREATM</a> <a title="EMJ 1.4 2016 page 35" href="http://viewer.zmags.com/publication/8d83f42a?page=35"> endothelial growth factor (VEGF) have attracted a</a> <a title="EMJ 1.4 2016 page 36" href="http://viewer.zmags.com/publication/8d83f42a?page=36"> in mCRC patients who had failed stand</a> <a title="EMJ 1.4 2016 page 37" href="http://viewer.zmags.com/publication/8d83f42a?page=37"> Table 2: Summary of the results of complet</a> <a title="EMJ 1.4 2016 page 38" href="http://viewer.zmags.com/publication/8d83f42a?page=38"> Table 2 continued. Trial name/ID Indication </a> <a title="EMJ 1.4 2016 page 39" href="http://viewer.zmags.com/publication/8d83f42a?page=39"> also showed a longer survival trend compared to p</a> <a title="EMJ 1.4 2016 page 40" href="http://viewer.zmags.com/publication/8d83f42a?page=40"> nitric oxide levels and increased endothelin</a> <a title="EMJ 1.4 2016 page 41" href="http://viewer.zmags.com/publication/8d83f42a?page=41"> cancers who have progressed on prior standard the</a> <a title="EMJ 1.4 2016 page 42" href="http://viewer.zmags.com/publication/8d83f42a?page=42"> who failed one prior line of oxaliplatin- contain</a> <a title="EMJ 1.4 2016 page 43" href="http://viewer.zmags.com/publication/8d83f42a?page=43"> in patients with colorectal carcinoma: Data f</a> <a title="EMJ 1.4 2016 page 44" href="http://viewer.zmags.com/publication/8d83f42a?page=44"> COILS FOR THE TREATMENT OF ADVANCED EMPHYS</a> <a title="EMJ 1.4 2016 page 45" href="http://viewer.zmags.com/publication/8d83f42a?page=45"> Table 1: Overview Pilot Studies P</a> <a title="EMJ 1.4 2016 page 46" href="http://viewer.zmags.com/publication/8d83f42a?page=46"> Table 1 continued. Randomised Clinical Tri</a> <a title="EMJ 1.4 2016 page 47" href="http://viewer.zmags.com/publication/8d83f42a?page=47"> fluoroscopic guidance. About 10 coils per lobe are</a> <a title="EMJ 1.4 2016 page 48" href="http://viewer.zmags.com/publication/8d83f42a?page=48"> Table 2: Demographic and bronchoscopic procedure </a> <a title="EMJ 1.4 2016 page 49" href="http://viewer.zmags.com/publication/8d83f42a?page=49"> Significantly different findings were a</a> <a title="EMJ 1.4 2016 page 50" href="http://viewer.zmags.com/publication/8d83f42a?page=50"> Experience at Pourtales Hospital, Neuchâtel, Swit</a> <a title="EMJ 1.4 2016 page 51" href="http://viewer.zmags.com/publication/8d83f42a?page=51"> 14. DeCamp MM Jr et al. Lung volume reduction sur</a> <a title="EMJ 1.4 2016 page 52" href="http://viewer.zmags.com/publication/8d83f42a?page=52"> 52 EUROPEAN MEDICAL JOURNAL • December 2016 </a> <a title="EMJ 1.4 2016 page 53" href="http://viewer.zmags.com/publication/8d83f42a?page=53"> NON-TRANSFUSION-DEPENDENT THALASSAEMIA: A PANORAM</a> <a title="EMJ 1.4 2016 page 54" href="http://viewer.zmags.com/publication/8d83f42a?page=54"> Iron overload • Diabetes mellitus • Failu</a> <a title="EMJ 1.4 2016 page 55" href="http://viewer.zmags.com/publication/8d83f42a?page=55"> as subcategories of these three processes. In thi</a> <a title="EMJ 1.4 2016 page 56" href="http://viewer.zmags.com/publication/8d83f42a?page=56"> Extramedullary Haematopoiesis As previously men</a> <a title="EMJ 1.4 2016 page 57" href="http://viewer.zmags.com/publication/8d83f42a?page=57"> and spontaneous abortion.40 A series by Nassar et</a> <a title="EMJ 1.4 2016 page 58" href="http://viewer.zmags.com/publication/8d83f42a?page=58"> hand, deferiprone, which is the first oral </a> <a title="EMJ 1.4 2016 page 59" href="http://viewer.zmags.com/publication/8d83f42a?page=59"> TDT/TM Thalassaemia major NTDT* Indications</a> <a title="EMJ 1.4 2016 page 60" href="http://viewer.zmags.com/publication/8d83f42a?page=60"> all patients, both medically and psychologic</a> <a title="EMJ 1.4 2016 page 61" href="http://viewer.zmags.com/publication/8d83f42a?page=61"> aiming for lowering complication rates across a </a> <a title="EMJ 1.4 2016 page 62" href="http://viewer.zmags.com/publication/8d83f42a?page=62"> CLINICAL MANAGEMENT OF DRUG-INDUCED </a> <a title="EMJ 1.4 2016 page 63" href="http://viewer.zmags.com/publication/8d83f42a?page=63"> an overview of the current approaches in managing</a> <a title="EMJ 1.4 2016 page 64" href="http://viewer.zmags.com/publication/8d83f42a?page=64"> clinical trial is examining the use of com</a> <a title="EMJ 1.4 2016 page 65" href="http://viewer.zmags.com/publication/8d83f42a?page=65"> dyskinesia on quality of life. On the other hand,</a> <a title="EMJ 1.4 2016 page 66" href="http://viewer.zmags.com/publication/8d83f42a?page=66"> A B Severity of dyskinesia lt </a> <a title="EMJ 1.4 2016 page 67" href="http://viewer.zmags.com/publication/8d83f42a?page=67"> HOW COULD THE PROPOSED APPROACH BE IMPLEMENTED? </a> <a title="EMJ 1.4 2016 page 68" href="http://viewer.zmags.com/publication/8d83f42a?page=68"> Feedback could be provided through a simple</a> <a title="EMJ 1.4 2016 page 69" href="http://viewer.zmags.com/publication/8d83f42a?page=69"> 2010;362(22):2077-91. 28. Fine J et al. Long-term</a> <a title="EMJ 1.4 2016 page 70" href="http://viewer.zmags.com/publication/8d83f42a?page=70"> OCCUPATIONAL ALLERGIES: A BRIEF REVIEW *Mohammad </a> <a title="EMJ 1.4 2016 page 71" href="http://viewer.zmags.com/publication/8d83f42a?page=71"> Table 1: The classification of work-related asthma</a> <a title="EMJ 1.4 2016 page 72" href="http://viewer.zmags.com/publication/8d83f42a?page=72"> Management Patient quality of life can be severel</a> <a title="EMJ 1.4 2016 page 73" href="http://viewer.zmags.com/publication/8d83f42a?page=73"> surgical therapy (in some cases) could also</a> <a title="EMJ 1.4 2016 page 74" href="http://viewer.zmags.com/publication/8d83f42a?page=74"> antigen exposure or chronic fibrotic changes, with</a> <a title="EMJ 1.4 2016 page 75" href="http://viewer.zmags.com/publication/8d83f42a?page=75"> However, by eradication of the causative factor, </a> <a title="EMJ 1.4 2016 page 76" href="http://viewer.zmags.com/publication/8d83f42a?page=76"> diagnosis. In general, the supportive and inspect</a> <a title="EMJ 1.4 2016 page 77" href="http://viewer.zmags.com/publication/8d83f42a?page=77"> 39. Lacasse Y et al. Classification of </a> <a title="EMJ 1.4 2016 page 78" href="http://viewer.zmags.com/publication/8d83f42a?page=78"> ALLERGEN-SPECIFIC IMMUNOTHERAPY </a> <a title="EMJ 1.4 2016 page 79" href="http://viewer.zmags.com/publication/8d83f42a?page=79"> side effects.10 In depot extracts the allergen is</a> <a title="EMJ 1.4 2016 page 80" href="http://viewer.zmags.com/publication/8d83f42a?page=80"> Table 1: Considerations in different indications </a> <a title="EMJ 1.4 2016 page 81" href="http://viewer.zmags.com/publication/8d83f42a?page=81"> with beta blockers (due to the risk of refractory</a> <a title="EMJ 1.4 2016 page 82" href="http://viewer.zmags.com/publication/8d83f42a?page=82"> B Allergens, toxins, pollutants </a> <a title="EMJ 1.4 2016 page 83" href="http://viewer.zmags.com/publication/8d83f42a?page=83"> Table 2: Factors associated with adverse reaction</a> <a title="EMJ 1.4 2016 page 84" href="http://viewer.zmags.com/publication/8d83f42a?page=84"> 0.02% experienced Grade 3 and 4, respectively). T</a> <a title="EMJ 1.4 2016 page 85" href="http://viewer.zmags.com/publication/8d83f42a?page=85"> in respiratory disease.59 Two main form</a> <a title="EMJ 1.4 2016 page 86" href="http://viewer.zmags.com/publication/8d83f42a?page=86"> Database Syst Rev. 2010;(8):CD001186. 21. Boyle R</a> <a title="EMJ 1.4 2016 page 87" href="http://viewer.zmags.com/publication/8d83f42a?page=87"> 65. Omnes LF et al. Pharmacoeconomic assessment </a> <a title="EMJ 1.4 2016 page 88" href="http://viewer.zmags.com/publication/8d83f42a?page=88"> EUROPEAN MEDICAL JOURNAL provides influential arti</a> <a title="EMJ 1.4 2016 page 89" href="http://viewer.zmags.com/publication/8d83f42a?page=89"> MANAGEMENT OF CARDIOVASCULAR RISK FACTORS </a> <a title="EMJ 1.4 2016 page 90" href="http://viewer.zmags.com/publication/8d83f42a?page=90"> Genetic factors Visceral obesity Environmental </a> <a title="EMJ 1.4 2016 page 91" href="http://viewer.zmags.com/publication/8d83f42a?page=91"> Diabetes mellitus Platelets Hyperglycaemia Insul</a> <a title="EMJ 1.4 2016 page 92" href="http://viewer.zmags.com/publication/8d83f42a?page=92"> are higher in combination compared with eac</a> <a title="EMJ 1.4 2016 page 93" href="http://viewer.zmags.com/publication/8d83f42a?page=93"> blockers are an effective treatment for hypertens</a> <a title="EMJ 1.4 2016 page 94" href="http://viewer.zmags.com/publication/8d83f42a?page=94"> cigarettes smoked per day, while former smokers h</a> <a title="EMJ 1.4 2016 page 95" href="http://viewer.zmags.com/publication/8d83f42a?page=95"> Screening Tests for Asymptomatic Cardiovascular D</a> <a title="EMJ 1.4 2016 page 96" href="http://viewer.zmags.com/publication/8d83f42a?page=96"> food groups, and eating patterns in the managemen</a> <a title="EMJ 1.4 2016 page 97" href="http://viewer.zmags.com/publication/8d83f42a?page=97"> 63. Pignone M et al. Aspirin for primary preventi</a> <a title="EMJ 1.4 2016 page 98" href="http://viewer.zmags.com/publication/8d83f42a?page=98"> ROLE OF COAGULATION FACTOR CONCENTRATES</a> <a title="EMJ 1.4 2016 page 99" href="http://viewer.zmags.com/publication/8d83f42a?page=99"> status can deteriorate rapidly. It is thus import</a> <a title="EMJ 1.4 2016 page 100" href="http://viewer.zmags.com/publication/8d83f42a?page=100"> FFP can contain variable but near normal levels o</a> <a title="EMJ 1.4 2016 page 101" href="http://viewer.zmags.com/publication/8d83f42a?page=101"> Fibrinogen Concentrates With regard to fibrinogen </a> <a title="EMJ 1.4 2016 page 102" href="http://viewer.zmags.com/publication/8d83f42a?page=102"> improved clot firmness, as measured by ROTEM, sign</a> <a title="EMJ 1.4 2016 page 103" href="http://viewer.zmags.com/publication/8d83f42a?page=103"> tested in parallel using both methods, transfusio</a> <a title="EMJ 1.4 2016 page 104" href="http://viewer.zmags.com/publication/8d83f42a?page=104"> CONCLUSION In summary, there is a need to better</a> <a title="EMJ 1.4 2016 page 105" href="http://viewer.zmags.com/publication/8d83f42a?page=105"> 35. Solomon C et al. Safety of fibrinogen concentr</a> <a title="EMJ 1.4 2016 page 106" href="http://viewer.zmags.com/publication/8d83f42a?page=106"> GENE DELIVERY FROM STENTS FOR PREVENTION </a> <a title="EMJ 1.4 2016 page 107" href="http://viewer.zmags.com/publication/8d83f42a?page=107"> wall transducibility with viral and non-viral vec</a> <a title="EMJ 1.4 2016 page 108" href="http://viewer.zmags.com/publication/8d83f42a?page=108"> Platelet-derived growth factor (PDGF) is </a> <a title="EMJ 1.4 2016 page 109" href="http://viewer.zmags.com/publication/8d83f42a?page=109"> vectors were investigated in the context of stent</a> <a title="EMJ 1.4 2016 page 110" href="http://viewer.zmags.com/publication/8d83f42a?page=110"> and can cause embolisation of distal vasculature.</a> <a title="EMJ 1.4 2016 page 111" href="http://viewer.zmags.com/publication/8d83f42a?page=111"> adaptors, using N-hydroxysuccinimidyl ester</a> <a title="EMJ 1.4 2016 page 112" href="http://viewer.zmags.com/publication/8d83f42a?page=112"> coronary arteries: contemporary practice in real </a> <a title="EMJ 1.4 2016 page 113" href="http://viewer.zmags.com/publication/8d83f42a?page=113"> 46. Ma G et al. Anchoring of self-assembled plasm</a> <a title="EMJ 1.4 2016 page 114" href="http://viewer.zmags.com/publication/8d83f42a?page=114"> REVOLUTION OF DRUG-ELUTING CORONARY STENTS: </a> <a title="EMJ 1.4 2016 page 115" href="http://viewer.zmags.com/publication/8d83f42a?page=115"> now faced with their own challenges of late stent</a> <a title="EMJ 1.4 2016 page 116" href="http://viewer.zmags.com/publication/8d83f42a?page=116"> Table 1: Appraisal of design-related characterist</a> <a title="EMJ 1.4 2016 page 117" href="http://viewer.zmags.com/publication/8d83f42a?page=117"> Table 1 continued. Stent name Manufacturer </a> <a title="EMJ 1.4 2016 page 118" href="http://viewer.zmags.com/publication/8d83f42a?page=118"> Table 2: Appraisal of design-related characterist</a> <a title="EMJ 1.4 2016 page 119" href="http://viewer.zmags.com/publication/8d83f42a?page=119"> Table 2 continued. Stent name Manufacturer St</a> <a title="EMJ 1.4 2016 page 120" href="http://viewer.zmags.com/publication/8d83f42a?page=120"> at 1 year were lower with sirolimus-eluting stent</a> <a title="EMJ 1.4 2016 page 121" href="http://viewer.zmags.com/publication/8d83f42a?page=121"> factors, a hybrid-cell structure comprising a mix</a> <a title="EMJ 1.4 2016 page 122" href="http://viewer.zmags.com/publication/8d83f42a?page=122"> First Thick struts,</a> <a title="EMJ 1.4 2016 page 123" href="http://viewer.zmags.com/publication/8d83f42a?page=123"> coating inhibits smooth cell proliferation all ov</a> <a title="EMJ 1.4 2016 page 124" href="http://viewer.zmags.com/publication/8d83f42a?page=124"> • Eluting an ‘olimus’ drug (e.g. sirolimus, </a> <a title="EMJ 1.4 2016 page 125" href="http://viewer.zmags.com/publication/8d83f42a?page=125"> 23. Abizaid A, Costa JR Jr. New drug-</a> <a title="EMJ 1.4 2016 page 126" href="http://viewer.zmags.com/publication/8d83f42a?page=126"> SUBSCRIBE TO RECEIVE THE LATEST PUBLICATIONS, NE</a>